via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted
communications organization engaged in connecting public companies
to the investment community, is pleased to announce the release of
the latest episode of The Stock2Me Podcast as part of its
sustained effort to provide specialized content distribution via
widespread syndication channels.
The Stock2Me Podcast features a fascinating array of companies
and individuals, many of whom are actively revolutionizing age-old
business practices within their respective markets. Stock2Me’s
latest podcast features Chris Bunka, Chairman & CEO of Lexaria
Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug
delivery platforms.
To begin the interview, Bunka provided a summary of Lexaria’s
business model, which is focused on leveraging the company’s
proprietary DehydraTECH™ drug delivery technology.
“[Lexaria has] developed a drug delivery technology that’s quite
unique,” Bunka said. “What our technology does is it allows people
to swallow any number of various drugs or active pharmaceutical
ingredients (APIs) and basically allow a larger proportion of the
drug to … get into the bloodstream and reach the site of action.
That is what our technology is focused on, and, because we’re so
good at it, we’re actually seeing applications in all sorts of
different business sectors, be it cannabidiol, nicotine for oral
delivery, antiviral drugs and others. … We do not sell any drugs
ourselves, but we do sell or ‘rent’ our technology.”
Bunka then discussed his professional background and the team
behind Lexaria.
“I’ve been in a number of different industry sectors over what
is now a 40-year career – construction and real estate development,
natural resources and technology. … I’ve been with Lexaria a long
time. My president, John Docherty, and I are the two people who are
mostly responsible for the current business lines,” he added. “I’m
delighted to be able to work on my final project of my career,
which will be Lexaria. It’s the most exciting thing I’ve ever
worked on in my life, and I’m really, really fortunate to be part
of the team that we have at Lexaria, which has some incredible
scientists and businesspeople involved in the company.”
Bunka next highlighted Lexaria’s recent transformative steps to
position itself for accelerated growth.
“Our company kind of had a rebirth in January 2021. … We
completed a 1-for-30 reverse stock split,” Bunka explained. “That
was really hard, and just so you all know, I was the biggest
shareholder. I am still the biggest shareholder. I took a big hit
on my own holdings, but we had to do that to make the company
attractive for future shareholders. … We got listed on Nasdaq in
January and completed an $11 million financing. That was the
biggest financing in the history of the company, and it transformed
us. … We were able to step on the gas pedal and basically work on
our research and development and our commercial studies at a 5-10x
higher pace than anything we could do in the past. Therefore, this
year, we’ve done more work than we did in the five years previous –
all put together.”
Join IBN’s Stuart Smith and Chris Bunka, Chairman & CEO of
Lexaria Bioscience Corp. (NASDAQ: LEXX), as they explore Lexaria’s
accelerated development efforts in recent months and the company’s
ambitious goals for the remainder of 2021 and beyond.
To hear the whole podcast and subscribe for future episodes,
visit https://podcast.stock2me.com.
The latest installment of The Stock2Me Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers and the growing IBN Podcast
Series. For more than 15 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s patented drug delivery technology,
DehydraTECH™, improves the way active pharmaceutical ingredients
(APIs) enter the bloodstream by promoting more effective oral
delivery. Since 2016, DehydraTECH has repeatedly demonstrated the
ability to increase bio-absorption with cannabinoids and nicotine
by up to 5-10x, reduce time of onset from 1-2 hours to minutes and
mask unwanted tastes; it is also being evaluated for orally
administered anti-viral drugs, non-steroidal anti-inflammatory
drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability
to deliver some drugs more effectively across the blood brain
barrier. Lexaria operates a licensed in-house research laboratory
and holds a robust intellectual property portfolio with 21 patents
granted and over 50 patents pending worldwide. For more
information, visit the company’s website at
www.lexariabioscience.com.
About IBN
IBN (InvestorBrandNetwork) consists of financial brands
introduced to the investment public over the course of 15+ years.
With IBN, we have amassed a collective audience of millions of
social media followers. These distinctive investor brands aim to
fulfill the unique needs of a growing base of client-partners. IBN
will continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized
teams of experts to serve our increasingly diversified list of
clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN
provides: (1) access to a network of wire solutions via
InvestorWire to reach all target markets, industries and
demographics in the most effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3) enhanced press
release solutions to ensure maximum impact; (4) full-scale
distribution to a growing social media audience; (5) a full array
of corporate communications solutions; and (6) a total news
coverage solution.
For more information, please visit
https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website, applicable to all content provided by
IBN wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Sep 2023 to Sep 2024